Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...

Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up (BPT) – Meet Chris Wright, a professional basketball player and ...

Key updates in disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) forum are reported ...

A study found brain atrophy progresses more slowly with age in RRMS, highlighting the need to factor age into MS clinical ...

--TG Therapeutics, Inc., today announced updated data presentations including new six-year data from the ULTIMATE I& II Phase 3 trials evaluating BRIUMVI ® in patients with relapsing forms of multiple ...

TG Therapeutics, Inc. announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, highlighting its efficacy for ...

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

(RTTNews) - Sandoz said that the U.S. Food and Drug Administration approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. Tyruko is approved to treat all indications ...

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...